个人中心 - 老虎社区

LIHUI

IP属地：未知

帖子 · 18帖子 · 18
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- LIHUILIHUI
  ·2021-07-12
  .
  Oil Slips on Growing Threat of Delta Variant to Demand
  (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg
  Oil Slips on Growing Threat of Delta Variant to Demand
  497 评论
  2
  分享
  举报
- LIHUILIHUI
  ·2021-07-12
  .
  Oil Slips on Growing Threat of Delta Variant to Demand
  (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg
  Oil Slips on Growing Threat of Delta Variant to Demand
  349 评论
  3
  分享
  举报
- LIHUILIHUI
  ·2021-06-08
  Like please
  Controversial Biogen Alzheimer Drug Wins FDA Approval
  In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's
  Controversial Biogen Alzheimer Drug Wins FDA Approval
  586 1
  1
  分享
  举报
- LIHUILIHUI
  ·2021-06-04
  .
  非常抱歉，此主贴已删除
  621 1
  4
  分享
  举报
- LIHUILIHUI
  ·2021-06-03
  .
  非常抱歉，此主贴已删除
  471 评论
  1
  分享
  举报
- LIHUILIHUI
  ·2021-06-02
  .
  AMC Stock Is Surging Again. How to Make Sense of the Move.
  AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th
  AMC Stock Is Surging Again. How to Make Sense of the Move.
  524 评论
  点赞
  分享
  举报
- LIHUILIHUI
  ·2021-06-01
  .
  非常抱歉，此主贴已删除
  655 1
  2
  分享
  举报
- LIHUILIHUI
  ·2021-06-01
  Weeee
  Zoom Video to Report Q1 Earnings: What's in the Cards?
  Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte
  Zoom Video to Report Q1 Earnings: What's in the Cards?
  935 1
  点赞
  分享
  举报
- LIHUILIHUI
  ·2021-05-28
  .
  非常抱歉，此主贴已删除
  625 4
  1
  分享
  举报
- LIHUILIHUI
  ·2021-05-27
  .guu ya n
  527 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3579418112520180","uuid":"3579418112520180","gmtCreate":1616324571094,"gmtModify":1620830636840,"name":"LIHUI","pinyin":"lihui","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":55,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1631889244205,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1631889244216,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142064787","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1631889244259,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","kind":"news","pubTimestamp":1623080895,"share":"https://www.laohu8.com/m/news/1133110564?lang=&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p>\n<p>AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p>\n<p>The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p>\n<p>The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p>\n<p>As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p>\n<p>Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p>\n<p>FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p>\n<p>Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p>\n<p><img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p>\n<p><i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p>\n<p><i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p>\n<p><i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p>\n<p><i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p>\n<p><i><b>What the Data Show</b></i></p>\n<p><i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p>\n<p><i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p>\n<p><i><b>Accelerated Approval</b></i></p>\n<p><i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p>\n<p><i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p>\n<p><i><b>The Devastation of Alzheimer’s Disease</b></i></p>\n<p><i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p>\n<p><i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p>\n<p><i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p>\n<p><i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.  The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint.  In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion.  It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.  Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.  As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1631889244270,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118594655","repostId":"2140247164","repostType":4,"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1631889244285,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111320436","repostId":"2140448417","repostType":4,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1631889244292,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".&nbsp;","listText":".&nbsp;","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111963117","repostId":"1188552613","repostType":4,"repost":{"id":"1188552613","kind":"news","pubTimestamp":1622627641,"share":"https://www.laohu8.com/m/news/1188552613?lang=&edition=full","pubTime":"2021-06-02 17:54","market":"us","language":"en","title":"AMC Stock Is Surging Again. How to Make Sense of the Move.","url":"https://stock-news.laohu8.com/highlight/detail?id=1188552613","media":"Barrons","summary":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th","content":"<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p>\n<p>But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p>\n<p>Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p>\n<p>Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p>\n<p>AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p>\n<p>So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p>\n<p>Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p>\n<p>The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p>\n<p>In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p>\n<p>Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p>\n<p>If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p>\n<p>Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p>\n<p>There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p>\n<p>Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p>\n<p>AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p>\n<p>There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p>\n<p>AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p>\n<p>Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p>\n<p>Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p>\n<p>And that’s just another way of saying that AMC bulls are a long way from making the math work.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Is Surging Again. How to Make Sense of the Move.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Is Surging Again. How to Make Sense of the Move.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into ...</p>\n\n<a href=\"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188552613","content_text":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.\nBut it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.\nShares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.\nEven if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.\nAMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.\nSo, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.\nBack then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.\nThe upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.\nIn those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.\nMaybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.\nIf AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.\nThen, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.\nThere are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.\nAlso, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.\nAMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.\nThere is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.\nAMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.\nWall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.\nAnalysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.\nAnd that’s just another way of saying that AMC bulls are a long way from making the math work.","news_type":1},"isVote":1,"tweetType":1,"viewCount":524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1631889244304,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119454643","repostId":"2140617694","repostType":4,"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1631889244319,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119455704","repostId":"2138889344","repostType":4,"repost":{"id":"2138889344","kind":"news","pubTimestamp":1622546894,"share":"https://www.laohu8.com/m/news/2138889344?lang=&edition=full","pubTime":"2021-06-01 19:28","market":"us","language":"en","title":"Zoom Video to Report Q1 Earnings: What's in the Cards?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138889344","media":"Zacks","summary":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte","content":"<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p>Let’s see how things have shaped up for this announcement.</p><h3>Factors to Watch</h3><p>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><h3>Key Q1 Highlights</h3><p>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video to Report Q1 Earnings: What's in the Cards?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video to Report Q1 Earnings: What's in the Cards?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are...</p>\n\n<a href=\"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138889344","content_text":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.Zoom Video Communications, Inc. Price and EPS SurpriseZoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. QuoteZoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.Let’s see how things have shaped up for this announcement.Factors to WatchZoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of Atlassian, ServiceNow and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.However, Zoom Video continues to face significant competition from the likes of Cisco, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.Key Q1 HighlightsDuring the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1631889244334,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/134326282","repostId":"2138107027","repostType":4,"isVote":1,"tweetType":1,"viewCount":625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1631889244340,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135084783","isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}